Skip to main content
. 2016 Sep 1;6:32087. doi: 10.1038/srep32087

Figure 6. CsA and FK506 pretreatment enhance viability and decrease motility in PAN-treated podocytes in vitro.

Figure 6

MTT assays of podocyte viability 24 h after CsA (A) or FK506 (B) treatment at indicated concentrations. Viability in the control group (0.1% DMSO) was set at 100% (Δp < 0.05 vs PAN group). (C) Light microscopy of podocyte morphology 48 h after CsA and FK506 treatment. Original magnification, X200. (D) Transwell migration assays of podocyte motility 24 h after CsA and FK506 treatment (**P < 0.01). Original magnification, X100. All experiments were performed at least 3 times, and the results were shown as mean ± SD.